Atherosclerosis Therapeutics Market by Product and Geography - Forecast and Analysis 2022-2026

The atherosclerosis therapeutics market share is expected to increase by USD 3.44 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.66%.

This atherosclerosis therapeutics market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers atherosclerosis therapeutics market segmentations by product (small molecules and biologics) and geography (North America, Europe, Asia, and Rest of World (ROW)). The atherosclerosis therapeutics market report also offers information on several market vendors, including Amgen Inc., AstraZeneca Plc, Dr. Reddys Laboratories Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Ionis Pharmaceuticals Inc., Merck and Co. Inc., Novartis AG, Regeneron Pharmaceuticals Inc., Sanofi SA, Viatris Inc., GlaxoSmithKline Plc, and Pfizer Inc. among others.

What will the Atherosclerosis Therapeutics Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Atherosclerosis Therapeutics Market Size for the Forecast Period and Other Important Statistics

 

Atherosclerosis Therapeutics Market: Key Drivers, Trends, and Challenges

The increasing risk factors for atherosclerosis is notably driving the atherosclerosis therapeutics market growth, although factors such as side-effects associated with atherosclerosis therapeutics may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the atherosclerosis therapeutics industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Atherosclerosis Therapeutics Market Driver

The increasing risk factors for atherosclerosis is one of the key factors supporting the atherosclerosis therapeutics market growth. According to the NIH, hypercholesterolemia affects one in 500 people in most countries. It is also estimated that a heterozygote contains two to three-fold times elevated plasma cholesterol level, whereas a homozygote has four to six-fold times elevation in plasma cholesterol level. Hence, the incidence of myocardial infarction is higher in homozygotes than in heterozygotes, and the susceptible age of getting myocardial infarction was calculated as 15 years and 60 years, respectively. Thus, other factors such as cigarette smoking, unhealthy eating habits, sleep deprivation, and lack of physical activities will lead to an increase in risk factors associated with atherosclerosis, which, in turn, induces the demand for atherosclerosis therapeutics, thereby contributing to the market growth.

Key Atherosclerosis Therapeutics Market Trend

Identification of new pathogenic targets is one of the key atherosclerosis therapeutics market trends that is contributing to the market growth. For instance, research has revealed that the infection with Porphyromonas gingivalis is associated with atherogenesis. P. gingivalis can stimulate the inflammatory response, thus accelerating the formation of atheroma. This further aggravates vascular inflammation through the released cytokines and chemokines, which induce the early development of atherosclerosis. Infections with C. pneumoniae and P. gingivalis are highly prevalent in both developing and developed regions. Hence, the identification of these pathogenic targets and their contribution to atherogenesis will significantly increase the identification of susceptible patient populations, which, in turn, will lead to an increase in demand for atherosclerosis therapeutics and will drive market growth during the forecast period.

Key Atherosclerosis Therapeutics Market Challenge

Side effects associated with atherosclerosis therapeutics is one of the factors hindering the atherosclerosis therapeutics market growth. For instance, ZOCOR is a cholesterol-lowering drug and is classified under statins. It is used as an adjunct to diet and exercise and acts by lowering the LDL cholesterol level in the blood. High LDL level is the major risk factor for atherosclerosis, and thus, ZOCOR is regarded as an important medication for preventing the formation of plaque. Considering the critical role of this drug in preventing or altering the process involved in atherogenesis, the drug is extensively used by patients with atherosclerosis. However, several research studies have revealed that the drug can cause muscular diseases, such as myopathy and rhabdomyolysis, a rare condition that leads to kidney failure. Therefore, the potent side-effects of atherosclerosis therapeutics impede the rationale behind using these drugs for the treatment of atherosclerosis, thereby negatively affecting the market growth.

This atherosclerosis therapeutics market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global atherosclerosis therapeutics market as a part of the pharmaceutical market within the overall healthcare industry. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the atherosclerosis therapeutics market during the forecast period.

Who are the Major Atherosclerosis Therapeutics Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

• Amgen Inc.
• AstraZeneca Plc
• Dr. Reddys Laboratories Ltd.
• Eli Lilly and Co.
• F. Hoffmann La Roche Ltd.
• Ionis Pharmaceuticals Inc.
• Merck and Co. Inc.
• Novartis AG
• Regeneron Pharmaceuticals Inc.
• Sanofi SA
• Viatris Inc.
• GlaxoSmithKline Plc
• Pfizer Inc.

 

This statistical study of the atherosclerosis therapeutics market encompasses successful business strategies deployed by the key vendors. The atherosclerosis therapeutics market is concentrated and the vendors are deploying growth strategies such as increasing efforts for drug approvals accompanied by robust R and D in this area to compete in the market.

Product Insights and News

• Amgen.com - The company offers atherosclerosis therapeutics such as Repatha (evolocumab) and optimized statin therapy.
• Astrazeneca.com - The company offers atherosclerosis therapeutics such as MEDI6012, a lecithin-cholesterol acyltransferase (LCAT), for the treatment of atherosclerosis in patients having experienced the most serious type of heart attack.
• Drreddys.com - The company offers atherosclerosis therapeutics such as DRL-17822.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The atherosclerosis therapeutics market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Atherosclerosis Therapeutics Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the atherosclerosis therapeutics market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for Atherosclerosis Therapeutics Market?

For more insights on the market share of various regions Request for a FREE sample now!

44% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for the atherosclerosis therapeutics market in North America. Market growth in this region will be faster than the growth of the market in other regions.

The increasing adoption of health insurance by patients has led to an increase in the purchase of atherosclerosis therapeutics for their treatment, which will facilitate the atherosclerosis therapeutics market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

The COVID-19 pandemic in 2020 certainly had a tremendous impact on the pharmaceutical business in North America. However, owing to the large-scale vaccination drives, activities resumed in manufacturing units for atherosclerosis therapeutic products in 2021 leading to a growth in the market in focus.

What are the Revenue-generating Product Segments in the Atherosclerosis Therapeutics Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The atherosclerosis therapeutics market share growth by the small molecules segment will be significant during the forecast period. High blood pressure is a major risk factor for atherosclerosis and may lead to serious complications, such as heart attack, stroke, and other cardiovascular events that may prove to be fatal. The use of small molecules cannot lead to the complete remission of atherosclerosis. However, these drugs can significantly reduce the risk of complications associated with atherosclerosis. Moreover, the manufacturing and regulatory approval process of small molecules are relatively simple when compared with biologics, which further prompts new players to enter the market to cater to the rising demand for small molecule drugs for the treatment of atherosclerosis. Such increasing demand for small molecule drugs will drive market growth during the forecast period.

This report provides an accurate prediction of the contribution of all the segments to the growth of the atherosclerosis therapeutics market size and actionable market insights on post COVID-19 impact on each segment.

 

Atherosclerosis Therapeutics Market Scope
Report Coverage	Details
Page number	120
Base year	2021
Forecast period	2022-2026
Growth momentum & CAGR	Accelerate at a CAGR of 5.66%
Market growth 2022-2026	$ 3.44 billion
Market structure	Concentrated
YoY growth (%)	5.13
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 44%
Key consumer countries	US, Canada, UK, Germany, and China
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	Amgen Inc., AstraZeneca Plc, Dr. Reddys Laboratories Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Ionis Pharmaceuticals Inc., Merck and Co. Inc., Novartis AG, Regeneron Pharmaceuticals Inc., Sanofi SA, Viatris Inc., GlaxoSmithKline Plc, and Pfizer Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Atherosclerosis Therapeutics Market Report?

• CAGR of the market during the forecast period 2022-2026
• Detailed information on factors that will drive atherosclerosis therapeutics market growth during the next five years
• Precise estimation of the atherosclerosis therapeutics market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the atherosclerosis therapeutics industry across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of atherosclerosis therapeutics market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch